Clinical trials: Deficiency Disease
HIV Infections
Investigation of V520 in a HIV Vaccine Dose Refinement Study (V520-027)(TERMINATED)
This study will test the safety and immunogenicity of an investigational Human Immunodeficiency Virus (HIV) vaccine. Immunogenicity will be measured by evaluating the immune response to several different dose levels.
- Trial name
- NCT00350623
- Testing
- MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose (V520), MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose (V520), MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose (V520)
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Vitamin D Deficiency
Safety of Vitamin D Supplementation in Older Persons
This study will evaluate the safety over 6 months of two different doses of vitamin D (cholecalciferol) in men and women age 65 and older. It will also evaluate if supplementation with vitamin D improves physical performance.
- Trial name
- NCT00681590
- Testing
- cholecalciferol (vitamin D)
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- University of Miami
HIV Infections, Kidney Diseases
Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients
Maraviroc (MVC) is a type of HIV medicine called a CCR5 inhibitor. This study will evaluate the safety and tolerability of MVC in HIV-infected adults receiving a kidney transplant.
- Trial name
- NCT02741323
- Testing
- Maraviroc
- Where
- 10 sites in United States
- Volunteers
- 97 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pre-Exposure Prophylaxis, HIV Infections
Testing Implementation Strategies to Improve Delivery of PrEP for Pregnant and Postpartum Women in Kenya
This study tests strategies for improving PrEP implementation in maternal and child health clinics using an interrupted time series.
- Conditions
- Pre-Exposure Prophylaxis, HIV Infections, Pregnancy Related
- Trial name
- PrEPARE (NCT05482360)
- Testing
- PrEP Optimization Interventions
- Where
- Kenya
- Volunteers
- 5,173 people, healthy volunteers welcome
- Sponsor
- University of Washington
Mental Health Issue, Hiv
Walk-in Therapy in Low Barrier Primary Care
The goals of the current research are to adapt an effective walk-in psychotherapy clinic intervention for the context of low-barrier primary care; and conduct a pilot implementation study in a low-barrier primary care clinic…
- Conditions
- Mental Health Issue, Hiv, Substance Use
- Trial name
- NCT06552325
- Testing
- Single Session Narrative Therapy
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- University of Washington
Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Cholecalciferol in Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency
This randomized pilot early phase I trial studies how well cholecalciferol works in treating patients with newly diagnosed non-Hodgkin lymphoma or chronic lymphocytic leukemia with low levels of vitamin D (vitamin D deficiency).
- Conditions
- Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, Untreated Chronic Lymphocytic Leukemia, Vitamin D Deficiency
- Trial name
- NCT02553447
- Testing
- Cholecalciferol, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 197 people
- Sponsor
- University of Nebraska
HIV Infections
An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy
The purpose of this study is to see if it is effective to give HIV positive patients recombinant interleukin-2 (rIL-2) in addition to anti-HIV therapy.
- Trial name
- ESPRIT (NCT00004978)
- Testing
- Recombinant interleukin-2 (rIL-2)
- Where
- 248 sites in United States, Argentina and 23 more
- Volunteers
- 4,150 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV/AIDS
HIV Oral Testing Infographic Experiment
Premised on the National AIDS Strategy's focus on identifying new HIV infections through increased HIV testing, the purpose of this formative pilot study is to develop and test an integrated HIV self-testing strategy that…
- Trial name
- HOTIE (NCT04061915)
- Testing
- Infographic Intervention, Paper-based HIV self-testing information
- Where
- United States
- Volunteers
- 322 people, healthy volunteers welcome
- Sponsor
- New York University
HIV Infections
Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents
First-line antiretroviral regimens are highly efficacious and generally well tolerated. However, as these regimens need to be taken life-long, there is growing concern about long-term toxicities associated with these regimens.
- Trial name
- NCT03682848
- Testing
- DTG + 3TC FDC
- Where
- 8 sites in Kenya, South Africa and 1 more
- Volunteers
- 32 people
- Sponsor
- ViiV Healthcare
AIDS
Evaluation of the Immune Response of a HIV Candidate Vaccine After Administration of One Chloroquine Dose
The purpose of this study is to evaluate the safety and reactogenicity of one booster dose of a HIV candidate vaccine after administration of one oral dose of chloroquine.
- Trial name
- NCT00972725
- Testing
- GSK Biologicals' HIV vaccine (732461), Chloroquine
- Where
- Belgium
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infection
Traditional Healer-initiated HIV Counseling and Testing in South Africa
The objective of this proposal is to conduct a pilot test of a program aimed at training traditional healers to conduct HIV testing and implementing HIV testing among people living in Bushbuckridge, South Africa.
- Trial name
- NCT05079347
- Testing
- HIV rapid test
- Where
- South Africa
- Volunteers
- 418 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Ataxia Telangiectasia
N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T)
This is a multinational, multicenter, open-label, rater-blinded prospective Phase II study which will assess the safety and efficacy of N-Acetyl-L-Leucine (IB1001) for the treatment of Ataxia-Telangiectasia (A-T).
- Trial name
- NCT03759678
- Testing
- IB1001
- Where
- 4 sites in United States, Germany and 2 more
- Volunteers
- 17 people
- Sponsor
- IntraBio Inc
Alpha-1 Antitrypsin Deficiency
Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency
Assessment of the safety and efficacy of intramuscular (IM) administration of a recombinant adenoassociated virus (rAAV) alpha-1 antitrypsin (AAT) vector (rAAV1-CB-hAAT) in AAT-deficient adults at three dosage levels [6.0 ×…
- Trial name
- NCT01054339
- Testing
- rAAV1-CB-hAAT
- Where
- 4 sites in United States, Ireland
- Volunteers
- 9 people
- Sponsor
- Beacon Therapeutics
HIV/AIDS, Tuberculosis
Drinkers' Intervention to Prevent Tuberculosis (DIPT Study)
There is an urgent global need to decrease the high mortality of tuberculosis (TB) in persons with HIV as TB is the leading cause of death among persons with HIV worldwide.
- Trial name
- DIPT (NCT03492216)
- Testing
- Incentives for negative EtG test, Incentives for positive IsoScreen test
- Where
- 2 sites in Uganda
- Volunteers
- 680 people
- Sponsor
- University of California, San Francisco
Hepatitis C, HIV Coinfection
Supporting Treatment Outcomes Among PWID
The goal of this study is to improve HCV care continuum outcomes for people who inject drugs (PWID), reduce potential onward transmission to others and improve HIV outcomes among those who are HIV/HCV coinfected.
- Trial name
- STOP-C (NCT04652804)
- Testing
- Low intensity HCV treatment adherence support, Medium intensity HCV treatment adherence support, High intensity HCV treatment adherence support
- Where
- India
- Volunteers
- 3,000 people
- Sponsor
- Johns Hopkins University
Human Immunodeficiency Virus, Metabolic Syndrome
2-5 Intermittent Caloric Restriction in HIV
Background: Weight gain can lead to obesity and diabetes even in people living with human immunodeficiency virus (HIV). Researchers want to see if the technique intermittent calorie restriction can help overweight people with HIV…
- Trial name
- 2-5toWIN (NCT03489109)
- Testing
- Intermittent fasting, Standard of Care
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters
The U.S. Department of Health and Human Services (HHS) guidelines recommend that HIV-infected people who have never received anti-HIV therapy be treated with a triple drug regimen (commonly called combination antiretroviral…
- Trial name
- NCT00851799
- Testing
- Emtricitabine/tenofovir disoproxil fumarate, Ritonavir, Atazanavir
- Where
- 26 sites in United States
- Volunteers
- 334 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Primary Immunodeficiency
Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%
Phase 3 multicenter, open-label study of safety, tolerability, efficacy, and pharmacokinetics (PK) of ProMetic's Immune Globulin Intravenous (Human) 10%, the investigational medicinal product [IMP]), in Adults and Children with…
- Trial name
- NCT02269163
- Testing
- Immune Globulin Intravenous, Prometic's Immune Globulin Intravenous 10%
- Where
- 13 sites in United States
- Volunteers
- 82 people
- Sponsor
- Prometic Biotherapeutics, Inc.
HIV Infection
A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248)
This multicenter, open-label, noncomparative study evaluates two oral formulations of raltegravir (MK-0518, film-coated tablet and chewable tablet) in combination with other antiretroviral agents for safety, tolerability, and…
- Trial name
- NCT01717287
- Testing
- Raltegravir Film-coated Tablet, Raltegravir Chewable Tablet, Other Anti-Retroviral Therapy
- Volunteers
- 32 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infection
Impact of a Human Papilloma Virus (HPV) Vaccine in HIV-Infected Young Women
The purpose of this study is to evaluate the immunogenicity, safety, tolerability, and behavioral impact of an HPV-6, -11, -16, -18 vaccine in HIV-infected young women.
- Trial name
- NCT00710593
- Testing
- HPV vaccine for strains -6, -11, -16, and -18
- Where
- 14 sites in United States, Puerto Rico
- Volunteers
- 99 people
- Sponsor
- University of North Carolina, Chapel Hill
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.